Abstract SIBO2Word文档格式.docx
- 文档编号:20483539
- 上传时间:2023-01-23
- 格式:DOCX
- 页数:13
- 大小:27.17KB
Abstract SIBO2Word文档格式.docx
《Abstract SIBO2Word文档格式.docx》由会员分享,可在线阅读,更多相关《Abstract SIBO2Word文档格式.docx(13页珍藏版)》请在冰豆网上搜索。
Abstract
OBJECTIVES:
Smallintestinalbacterialovergrowth(SIBO)isconsideredafrequentcauseofabdominalsymptomsinpatientswithsurgicallyalteredintestinalanatomyordysmotilityconditionsandisrecognizedasacontributingfactorintheexacerbationofirritablebowelsyndromesymptoms.Diagnostictestingcanbeusedtodetectthecondition.
METHODS:
Thestudygroupcomprisedpatientswhohadbreathhydrogenandmethanelactulosechallengetesting.Allofthepatientsweretreatedwithantibioticregimensthathaveshownbenefitfor
SIBO.Thelactulosechallengewasadministeredorallyat15g.Hydrogenandmethaneinexpiredairweremeasuredandhydrogenvalueswererecordedasthehydrogenplustwicethemethaneresult.Breathtestswereanalyzedforpositivitybasedonsingleandmultiplecriteriaoffastingbaselineelevation,earlyrise,andsecondpeakhydrogenrise.Globalimprovementofgastrointestinalsymptomswasassessedbytelephonecontactorrecordreview.
RESULTS:
Onehundredparticipants(78women)wereincludedintheanalysis.Themeanagewas51years.Atotalof15%ofparticipantsdidnotmeetanycriteriaonbreathtestingfor
SIBO;
73%hadafastingbaselineelevation>
10ppm;
and19%hadanincreaseof>
20ppmabovebaselineinthefirst20minutes,48%hada20-ppmincreaseinthefirst60minutes,and32%hadasecondincrease,reflectingacolonpeak.Overall,74%respondedtoacourseofantibiotics,determinedbyreportedimprovementinmorethanhalfofthesymptomswithin3months.Intotal,67%(10/15)ofthesubjectswhotestednegativefor
SIBO,byallcriteria,hadafavorableresponsetoantibiotics.Amongthosewithpositivehydrogenincreases,76.3%with1criterionresponded,66.7%with2criteriaresponded,84.6%with3responded,and76.9%with4responded.Afterantibiotictreatment,88.7%(47/53)ofthosewhohaddiarrheareportedimprovement,63.3%(19/30)withconstipationreportedimprovement,and74.3%(52/70)withbaselinebloatingexperiencedimprovement.Sixty-fiveofthe82patientswithpainordiscomfortreportedimprovement(79.3%).Ofthosetreatedwitharifaximinregimen,74.2%(49/66)reportedaresponsetotreatment.Twentyof28(71.4%)treatedwithamoxicillin/clavulanateexperiencedaclinicalresponse.
CONCLUSIONS:
Thesedatasuggestthattheresponsetoantibiotictherapyinpatientswithsuspected
SIBO
isnotpredictedbycarbohydrateSIBO
testingresultsandbringintoquestionthevalueofsuchtesting.
JBreathRes.
2016May10;
10
(2):
026010.doi:
10.1088/1752-7155/10/2/026010.
Hydrogensulphideinexhaledbreath:
apotentialbiomarkerforsmallintestinalbacterialovergrowthinIBS.
BanikGD1,
DeA,
SomS,
JanaS,
DaschakrabortySB,
ChaudhuriS,
PradhanM.
∙1DepartmentofChemical,BiologicalandMacromolecularSciences,SNBoseNationalCentreforBasicSciences,SaltLake,JDBlock,SectorIII,Kolkata700098,India.
Thereisapressingneedtodevelopanovelearly-detectionstrategyforthepreciseevolutionofsmallintestinalbacterialovergrowth(SIBO)inirritablebowelsyndrome(IBS)patients.Thecurrentmethodbasedonahydrogenbreathtest(HBT)forthedetectionof
ishighlycontroversial.HBThasmanylimitationsanddrawbacks.Itoftenfailstoindentify
whenIBSindividualshave'
non-hydrogen-producing'
colonicbacteria.Here,weshowthathydrogensulphide(H2S)inexhaledbreathisdistinctlyalteredfordiarrhea-predominantIBSindividualswithpositiveandnegative
bytheactivityofintestinalsulphate-reducingbacteria.Subsequently,byanalyzingtheexcretionkineticsofbreathH2S,wefoundamissinglinkbetweenbreathH2Sand
whenHBToftenfailstodiagnose
SIBO.Moreover,breathH2Scantrackthepreciseevolutionof
SIBO,evenaftertheeradicationofbacterialovergrowth.OurfindingssuggestthatthechangesinH2Sinthebacterialenvironmentmaycontributetothepathogenesisof
andthebreathH2Sasapotentialbiomarkerfornon-invasive,rapidandpreciseassessmentof
SIBOwithouttheendoscopy-basedmicrobialcultureofjejunalaspirates,andthusmayopennewperspectivesintothepathophysiologyof
inIBSsubjects.
TherapAdvGastroenterol.
9(3):
265-72.doi:
10.1177/1756283X15621231.Epub2015Dec31.
Refiningsmallintestinalbacterialovergrowthdiagnosisbymeansofcarbohydratespecificity:
aproof-of-conceptstudy.
EnkoD1,
Halwachs-BaumannG2,
StolbaR2,
ManggeH3,
Kriegshä
userG4.
∙1InstituteofClinicalChemistryandLaboratoryMedicineandDepartmentofGastroenterology,GeneralHospitalSteyr,Sierningerstraß
e170,4400Steyr,Austria.
∙2InstituteofClinicalChemistryandLaboratoryMedicine,GeneralHospitalSteyr,Steyr,Austria.
∙3ClinicalInstituteofMedicalandLaboratoryDiagnostics,MedicalUniversityofGraz,Graz,Austria.
∙4InstituteofClinicalChemistryandLaboratoryMedicineandDepartmentofGastroenterology,GeneralHospitalSteyr,Steyr,Austria.
BACKGROUND:
Diagnosisofsmallintestinalbacterialovergrowth(SIBO)remainschallenging.Thisstudyaimedatprovingthediagnosticconceptofcarbohydrate-specificSIBO(cs-SIBO)usingglucose,fructoseandsorbitolhydrogen(H2)/methane
(CH4)
breath
testing(HMBT).
Inthisstudy125patientsreferredtoouroutpatientclinicforSIBOtestingwereincluded.Allindividualsunderwentglucose(50g),fructose(25g)andsorbitol(12.5g)HMBTat3consecutivedays.Patientswithcs-SIBO(i.e.earlyH2/CH4peak)weregivenrifaximin(600mg/day)ina10-daytreatment.HMBTresultswerereassessedinasubsetofpatients3-6monthsafterantibiotictherapy.Inviewofcs-SIBOdiagnosis,agreementsbetweenHMBTresultsobtainedfordifferentsugarswerecalculatedusingCohen'
skappa(κ)with95%confidenceintervals(CIs).
Atotalof59(47.2%)patientspresentedanearlyH2/CH4peakwithoneormoresugars.Amongthese,21(16.8%),10(8.0%)and7(5.6%)individualshadapositiveHMBTresultwitheitherglucose,fructoseorsorbitol,respectively.Another21(16.8%)patientswithapositiveglucoseHMBTresultwerealsofoundpositivewithanearlyH2/CH4peakobtainedafteringestionoffructoseand/orsorbitol.Fairagreementwasobservedbetweenglucoseandfructose(κ=0.26,p=0.0018)andbetweenglucoseandsorbitol(κ=0.18,p=0.0178)HMBTresults.Slightagreementwasobservedbetweenfructoseandsorbitol(κ=0.03,p=0.6955)HMBTresultsonly.Successfulantibiotictherapywithrifaximincouldbedemonstratedin26/30(86.7%)ofpatientsasindicatedbynormalHMBTresultsandsymptomremission.
Combinedglucose,fructoseandsorbitolHMBThasthepotentialtooptimizecs-SIBOdiagnosis.Furthermore,themajorityofpatientswithcs-SIBOseemtobenefitfromrifaximintherapyregardlessofitscarbohydratespecificity.
MolClinOncol.
4(5):
883-887.Epub2016Mar7.
Prevalenceandtreatmentofsmallintestinalbacterialovergrowthinpostoperativepatientswithcolorectalcancer.
DengL1,
LiuY1,
ZhangD2,
LiY1,
XuL1.
∙1DepartmentofGastroenterology,QingdaoMunicipalHospitalAffiliatedtoQingdaoUniversity,Qingdao,Shandong266071,P.R.China.
∙2DepartmentofHepatobiliarySurgery,QingdaoMunicipalHospitalAffiliatedtoQingdaoUniversity,Qingdao,Shandong266071,P.R.China.
Toinvestigatetheprevalenceofsmallintestinalbacterialovergrowth(SIBO)inpatientswithcolorectalcancer(CRC)aftersurgicaltreatmentandobservewhethergastrointestinalsymptomsmayimprovewithrifaximin,43postoperativeCRCpatients(CRCgroup)and30healthyindividuals(normalgroup)weresubjectedtotheglucosehydrogen
test(GHBT).Allthepatientswereaskedtoevaluatethegastrointestinalsymptomsusingthevisualanaloguescale(VAS).SIBO-positivepatientswereadministeredrifaximinfor10daysonthebasisoftheoriginaltreatment.Afterthetreatment,thepatientswereaskedtoundergoGHBTandre-evaluatethegastrointestinalsymptomsscore(GISS).Theresultsdemonstratedthat18ofthe43postoperativepatientswithCRCwereSIBO-positive(41.86%),whichwassignificantlyhighercomparedwiththeincidenceinnormalcontrols(6.67%)(P<
0.05).GISSwashigherinSIBO-positivepatients(P<
0.05).Followingrifaximintreatment,6ofthe18(33.33%)SIBO-positivepatientshadimproved,asevaluatedbyGHBTandVAS.Additionally,theGISSintheSIBO-turned-negativegrouphadimprovedsignificantlycomparedwiththatinthenon-turned-negativegroup(P<
0.05).Thesymptomsofall18SIBO-positivepatientsfollowingrifaximintreatmentimprovednotably,particularlydiarrhea(P<
0.05).Inconclusion,postoperativeCRCpatientsaremorelikelytodevelopSIBOcomparedwithhealthyindividuals,andSIBOmayaggravatedigestivesymptoms.Theadministrationofrifaximinimprovedtheoverallgastrointestinalsymptoms,particularlydiarrhea,inSIBO-positivepatients.
BiomedResInt.
2016;
2016:
1064029.doi:
10.1155/2016/1064029.Epub2016Mar17.
LactuloseHydrogen
Breath
TestResultIsAssociatedwithAgeandGender.
NewberryC1,
TierneyA2,
Pickett-BlakelyO1.
∙1UniversityofPennsylvaniaPerelmanSchoolofMedicine,DivisionofGastroenterology,Philadelphia,PA19104,USA.
∙2UniversityofPennsylvaniaCenterforClinicalEpidemiologyandBiostatistics,Philadelphia,PA19104,USA.
Smallintestinalbac
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Abstract SIBO2
![提示](https://static.bdocx.com/images/bang_tan.gif)